Halberd (Halberd) Receivables Turnover : 0.00 (As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Halberd's Revenue for the six months ended in Jul. 2023 was $0.00 Mil. Halberd's average Accounts Receivable for the six months ended in Jul. 2023 was $0.00 Mil.

Halberd Receivables Turnover Historical Data

The historical data trend for Halberd's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Receivables Turnover Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Receivables Turnover

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Receivables Turnover	-	-	-

Competitive Comparison of Halberd's Receivables Turnover

For the Biotechnology subindustry, Halberd's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Halberd's Receivables Turnover falls into.

Halberd Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Halberd's Receivables Turnover for the fiscal year that ended in Jul. 2023 is calculated as

	Receivables Turnover (A: Jul. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jul. 2023 )	/ (	(Accounts Receivable (A: Jul. 2022 )	+	Accounts Receivable (A: Jul. 2023 ))	/	count )
=	0.003	/ (	(0	+	0)	/	1 )
=	0.003	/	0
=	N/A

Halberd's Receivables Turnover for the quarter that ended in Jul. 2023 is calculated as

	Receivables Turnover (Q: Jul. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jul. 2023 )	/ (	(Accounts Receivable (Q: Jul. 2022 )	+	Accounts Receivable (Q: Jul. 2023 ))	/	count )
=	0.003	/ (	(0	+	0)	/	1 )
=	0.003	/	0
=	N/A

Halberd (OTCPK:HALB) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Halberd Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Halberd's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236